Sabby Management’s Oncobiologics, Inc. Series A Warrant Expiring 2/18/2019 ONSIW Stock Holding History

Sabby Management’s Portfolio ONSIW Stock Details ONSIW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-89,644	Closed	-$3K	–	225
2017 Q4	$3K	Sell	89,644 -68,651	-43%	-$4.64K	﹤0.01%	159
2017 Q3	$18K	Sell	158,295 -179,818	-53%	-$23K	﹤0.01%	161
2017 Q2	$277K	Sell	338,113 -592,479	-64%	-$292K	0.02%	165
2017 Q1	$763K	Hold	930,592	–	–	0.04%	147
2016 Q4	$154K	Buy	930,592 +28,542	+3%	+$9.06K	0.01%	255
2016 Q3	$905K	Buy	902,050 +475,866	+112%	+$216K	0.03%	191
2016 Q2	$209K	Buy	+426,184	New	+$163K	0.01%	247

Other funds holding ONSIW

MWNA

Marshall Wace North America New York $23.5B AUM 46.46% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return

MIM

Monashee Investment Management Boston, Massachusetts $184M AUM 197.43% 1-Year Est. Return

Sabby Management's ONSIW Position: Q1 2018 in Review

Sabby Management sold out of Oncobiologics, Inc. Series A Warrant Expiring 2/18/2019 (ONSIW) in Q1 2018, closing a stake of 89,644 shares — an estimated $3K sold.

Sabby Management first reported a position in ONSIW in Q2 2016 and held it in 7 quarters. The position peaked at $905K in Q3 2016. 6 funds tracked by Wall St. Rank hold ONSIW as of Q1 2018.

Sabby Management reported no remaining Oncobiologics, Inc. Series A Warrant Expiring 2/18/2019 position as of Q1 2018 after selling out during the quarter.
Sabby Management sold 89,644 Oncobiologics, Inc. Series A Warrant Expiring 2/18/2019 shares in Q1 2018, an estimated $3K.
Sabby Management first reported a position in Oncobiologics, Inc. Series A Warrant Expiring 2/18/2019 in Q2 2016 and held it in 7 quarters.
Sabby Management's Oncobiologics, Inc. Series A Warrant Expiring 2/18/2019 position peaked at $905K in Q3 2016.
6 funds tracked by Wall St. Rank held Oncobiologics, Inc. Series A Warrant Expiring 2/18/2019 as of Q1 2018.

Based on Sabby Management's 13F filing for Q1 2018, filed 15 May 2018.